When are anabolic agents indicated for osteoporosis and what are the first‑line anabolic treatment options?

Anabolic Agents for Osteoporosis: Indications and First-Line Options

Anabolic agents are indicated for patients with very high fracture risk—specifically those with severe or multiple vertebral fractures, T-score ≤ -3.0 with fractures, or fracture on bisphosphonate therapy—and teriparatide or abaloparatide are the first-line anabolic options, with romosozumab as an alternative. 1

When to Use Anabolic Agents

Very High-Risk Criteria (Use Anabolics First-Line):

• Severe or multiple vertebral fractures 1
• Fracture risk ≥10% in the next 3 years 2
• Continued bone loss or new fracture while on bisphosphonates 1
• T-score ≤ -3.0 with existing fractures
• Glucocorticoid-induced osteoporosis in high-risk patients 3

Standard Risk (Use Bisphosphonates First):

For most postmenopausal women and men with osteoporosis who don't meet very high-risk criteria, bisphosphonates remain first-line therapy 4. However, the paradigm is shifting toward earlier anabolic use in appropriate candidates 5.

First-Line Anabolic Treatment Options

Teriparatide (PTH 1-34):

• Efficacy: 74% reduction in vertebral fractures, 39% reduction in nonvertebral fractures 1
• Dosing: Daily subcutaneous injection for up to 24 months maximum lifetime use
• Side effects: Dizziness, leg cramps, mild hypercalcemia 1
• Check serum calcium before starting 1

Abaloparatide (PTH-related protein analog):

• Efficacy: 87% reduction in vertebral fractures, 46% reduction in nonvertebral fractures 1
• Dosing: Daily subcutaneous injection for up to 24 months maximum lifetime use
• Side effects: Nausea, postural hypotension, dizziness, headache, palpitations (higher discontinuation rate than teriparatide) 1
• Check serum calcium before starting 1

Romosozumab (Anti-sclerostin antibody):

• Efficacy: Dual mechanism—increases bone formation while decreasing resorption; most effective for rapid BMD gains 6
• Dosing: Monthly subcutaneous injection for 12 months, followed by antiresorptive 4
• Considerations: Currently approved primarily for postmenopausal women; cardiovascular safety concerns require individualized risk assessment 7

Critical Treatment Sequencing Rules

After Anabolic Therapy (MANDATORY):

Always follow anabolic agents with antiresorptive therapy to maintain bone gains—the benefits of anabolics disappear within 12 months without subsequent antiresorptive treatment 1. Options include:

• Bisphosphonates (alendronate, zoledronate)
• Denosumab (anti-RANKL antibody)
• Raloxifene
• Hormone therapy 1

Prior Bisphosphonate Use:

Anabolics remain effective after bisphosphonate therapy, though the response may be slightly delayed and blunted 1. The VERO trial confirmed similar fracture reductions in prior bisphosphonate users versus treatment-naive patients 1.

Optimal Sequence:

Anabolic-first followed by antiresorptive is superior to the reverse sequence for high-risk patients 8, 3. Starting with bisphosphonates then switching to anabolics is less effective than starting with anabolics 5.

Common Pitfalls to Avoid

Black Box Warning (Both Teriparatide and Abaloparatide):

• Osteosarcoma risk in rats with lifelong exposure led to 24-month lifetime limit
• However, no increased human osteosarcoma risk after >1 million users since 2002 (only one case reported as of 2016) 1
• Do not use in patients with: Paget's disease, unexplained elevated alkaline phosphatase, prior radiation to skeleton, bone metastases, or hypercalcemia 1

Denosumab Rebound Risk:

If using denosumab after anabolics, never miss or delay doses—this causes severe rebound bone loss and multiple vertebral fractures within 18-24 months 1. Strict 6-month dosing adherence is essential.

Duration Limits:

• Teriparatide and abaloparatide: 24 months maximum lifetime use 1
• Romosozumab: 12 months maximum 4

Practical Considerations

Patient Barriers:

• Daily injections required for teriparatide/abaloparatide may limit adherence 1
• High cost compared to bisphosphonates; insurance coverage often limited 1
• Generic bisphosphonates should be used when appropriate to reduce costs 4

Monitoring:

• Check serum calcium before and during anabolic therapy 1
• Assess fracture risk, BMD response, and treatment adherence regularly
• Plan transition to antiresorptive therapy before completing anabolic course

The most recent high-quality evidence from the 2023 American College of Physicians guideline 4 and 2019 Endocrine Society guideline 1 establishes that while bisphosphonates remain first-line for most patients, anabolic agents should be prioritized upfront for very high-risk patients, followed by mandatory antiresorptive consolidation therapy.